lotiglipron + cyclosporine

This is a **combination of two drugs**: lotiglipron, an investigational oral small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist, and cyclosporine, an established immunosuppressant agent. Lotiglipron was developed by Pfizer for type 2 diabetes and obesity but its development was discontinued due to safety concerns. Cyclosporine is a calcineurin inhibitor used to prevent organ rejection and treat certain autoimmune diseases. There is no evidence that this specific drug combination is an approved or marketed product; the only data available relates to a pharmacokinetic interaction study where cyclosporine increased lotiglipron plasma concentrations when co-administered in healthy volunteers with overweight or obesity[1][2][3]. The combination does not represent a unique branded therapeutic but rather a co-administration examined for drug-drug interaction purposes.

Other names

lotiglipron + cyclosporine